Eli Lilly and Company (NYSE:LLY) cleared a notable regulatory hurdle on August 10, when Britain’s drug regulator authorized the company’s oral GLP-1 drug orforglipron, becoming the first country in Europe to approve the pill. Shares of LLY increased more than 2% in response to the announcement, a modest but insightful reaction for a company whose weight-loss franchise has become the single most important driver of its market value.
Small-Molecule Flexibility
The UK’s Medicines and Healthcare Products Regulatory Agency approved orforglipron, offered under the brand name Foundayo, for weight loss and maintenance in obese adults, as well as select overweight individuals with at least one weight-related health condition. The approval also addresses increasing blood sugar control in people with type 2 diabetes.
What sets Foundayo apart from Lilly’s other weight-loss medications, as well as the majority of the GLP-1 category in general, is the format. Unlike injectable drugs like Lilly’s Zepbound or Novo Nordisk A/S (NYSE:NVO)’s Ozempic, Foundayo is a small, non-peptide GLP-1 receptor agonist that is taken as a single daily tablet. It can also be taken at any time with no food or water restrictions, making it a far more convenient regimen than some oral peptide alternatives that require fasting windows around dosing.
The clinical data that supports the approval is strong. In the ATTAIN-1 trial, which tracked 3,127 individuals with obesity for 72 weeks, participants on the 36 mg dose lost an average of 11.2% of their body weight, as opposed to 2.1% on placebo, and more than half of those on that dose lost at least 10%.
NICE Evaluation Holds the Key to Mass Market Scale
The authorization is crucial, but it is not the final step. Foundayo is not currently available through the NHS in the UK, and the drug’s journey to that larger market is through the National Institute for Health and Care Excellence, which is completing its own cost-effectiveness study, with a decision expected on November 18. Until NICE decides, UK patients seeking the medicine will have to pay out of pocket or get it privately, a scenario that is already playing out with competing products in the category.
That competitor dynamic is essential to why this clearance matters commercially. Foundayo’s UK debut puts Eli Lilly and Company (NYSE:LLY) in direct rivalry with Novo Nordisk A/S (NYSE:NVO), whose own oral weight-loss drug, a tablet variant of Wegovy, was approved in the UK in June and has recently added higher-dose 9 mg and 25 mg options available via private prescribers. With both companies now offering oral GLP-1 options in the same market, the upcoming competition will likely be based on relative efficacy, tolerability, pricing, and, given the high global demand for these medications, manufacturing supply, all of which could influence prescribing patterns once NHS payment decisions are made.
Smart Money Sentiment
Institutional investors remain optimistic about Eli Lilly’s long-term market leadership in the metabolic health sector, despite small positioning adjustments early this year. According to 13F filing data, hedge fund ownership dropped marginally from 137 funds in the fourth quarter to 132 funds in the first quarter of 2026. Eli Lilly and Company (NYSE:LLY) is trading at a forward P/E ratio of 25.99x, indicating the premium attributed to its dual-engine growth narrative, which is driven by Mounjaro/Zepbound and its growing oral GLP-1 pipeline.
The Verdict
Short-term momentum investors should watch for the November 18 NICE payment ruling as the next key driver, with updates on scaled production and cash-pay pricing versus Novo Nordisk’s oral Wegovy guiding near-term trading direction. Overall, the approval validates Lilly’s oral small-molecule approach, with the forward P/E premium supported by earnings visibility as oral medications open the obesity market.
While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
